JP2023508052A5 - - Google Patents

Info

Publication number
JP2023508052A5
JP2023508052A5 JP2022538810A JP2022538810A JP2023508052A5 JP 2023508052 A5 JP2023508052 A5 JP 2023508052A5 JP 2022538810 A JP2022538810 A JP 2022538810A JP 2022538810 A JP2022538810 A JP 2022538810A JP 2023508052 A5 JP2023508052 A5 JP 2023508052A5
Authority
JP
Japan
Prior art keywords
methyl
oxo
naphthyridine
carbonitrile
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508052A (ja
JP7653440B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066507 external-priority patent/WO2021133750A1/en
Publication of JP2023508052A publication Critical patent/JP2023508052A/ja
Publication of JP2023508052A5 publication Critical patent/JP2023508052A5/ja
Application granted granted Critical
Publication of JP7653440B2 publication Critical patent/JP7653440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538810A 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換二環化合物 Active JP7653440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911053552 2019-12-23
IN201911053552 2019-12-23
PCT/US2020/066507 WO2021133750A1 (en) 2019-12-23 2020-12-22 Substituted bicyclic piperidine derivatives useful as t cell activators

Publications (3)

Publication Number Publication Date
JP2023508052A JP2023508052A (ja) 2023-02-28
JP2023508052A5 true JP2023508052A5 (cg-RX-API-DMAC7.html) 2023-12-07
JP7653440B2 JP7653440B2 (ja) 2025-03-28

Family

ID=74191945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538810A Active JP7653440B2 (ja) 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換二環化合物

Country Status (27)

Country Link
US (1) US11964973B2 (cg-RX-API-DMAC7.html)
EP (1) EP4081523B1 (cg-RX-API-DMAC7.html)
JP (1) JP7653440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119455A (cg-RX-API-DMAC7.html)
CN (1) CN114901660B (cg-RX-API-DMAC7.html)
AR (1) AR120823A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020412615B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022012195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163013A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001710A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008675A2 (cg-RX-API-DMAC7.html)
DK (1) DK4081523T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008848T3 (cg-RX-API-DMAC7.html)
FI (1) FI4081523T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250149T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070934T2 (cg-RX-API-DMAC7.html)
IL (1) IL294272B1 (cg-RX-API-DMAC7.html)
LT (1) LT4081523T (cg-RX-API-DMAC7.html)
MX (1) MX2022007842A (cg-RX-API-DMAC7.html)
PE (1) PE20221487A1 (cg-RX-API-DMAC7.html)
PL (1) PL4081523T3 (cg-RX-API-DMAC7.html)
PT (1) PT4081523T (cg-RX-API-DMAC7.html)
RS (1) RS66482B1 (cg-RX-API-DMAC7.html)
SI (1) SI4081523T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500102T1 (cg-RX-API-DMAC7.html)
TW (1) TWI843922B (cg-RX-API-DMAC7.html)
WO (1) WO2021133750A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2023122778A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
CN118946556A (zh) * 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
CN119998295A (zh) 2022-06-08 2025-05-13 因赛特公司 作为dgk抑制剂的三环三唑并化合物
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
WO2024137865A1 (en) * 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
JP2026504408A (ja) * 2023-02-02 2026-02-05 ビーワン メディシンズ ワン ゲーエムベーハー ヘテロ環式化合物
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CA2489560A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP5422204B2 (ja) * 2006-03-30 2014-02-19 国立大学法人 千葉大学 DGKα阻害剤を含有する抗癌剤
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
TW200829554A (en) 2006-09-29 2008-07-16 Tibotec Pharm Ltd Quinolinone derivatives
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
CN109575016B (zh) 2017-09-28 2022-01-04 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Similar Documents

Publication Publication Date Title
HRP20250149T1 (hr) Supstituirani biciklični derivati peridina korisni kao aktivatori t stanica
JP6853307B2 (ja) ヘテロアリール化合物およびそれらの使用
KR101671341B1 (ko) 다이아미노피리미딘 유도체 및 그의 제조방법
RU2529019C2 (ru) Модулирующие jak киназу хиназолиновые производные и способы их применения
ES2420860T3 (es) Compuestos amino-heterocíclicos usados como inhibidores de la PDE9
KR102835667B1 (ko) Parp14 억제제로서의 퀴나졸리논
JP6709786B2 (ja) Egfrモジュレーターとしての置換2−アミノピリミジン誘導体
KR101467858B1 (ko) mTOR 및 PI3K 억제제로서의 신규 피리미딘 화합물
AU2005229331A1 (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
JP7749602B2 (ja) アミドピリミドン誘導体
JP4917109B2 (ja) キナーゼ阻害剤としてのヘテロ二環式カルボキサミド
TW202246232A (zh) Tyk2抑制劑及其用途
JP2008526804A (ja) キナーゼ阻害剤としてのジ置換ウレア
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
KR20170086547A (ko) 헤테로아릴 화합물 및 이의 용도
CN105143215B (zh) 布鲁顿氏酪氨酸激酶抑制剂
AU2015303641A1 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
CA2724426A1 (en) Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP2012513480A (ja) Jak経路の阻害のための組成物および方法
JP2010513393A (ja) H1受容体アンタゴニストとしての4−ベンジル−l(2h)−フタラジノン
US20240059692A1 (en) New indazole derivatives
JP2025081599A (ja) Egfrキナーゼを阻害する化合物、調製方法、及びその使用
CN111315734A (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
JP2006241089A (ja) ピロロピリミジン誘導体またはその塩
EP4370212A1 (en) Heterocyclic compounds and uses thereof